Document:

Exhibit 10.1

 

AMENDMENT NO. 7 AGREEMENT

 

This Amendment No. 7 Agreement (this “Amendment”)
is dated as of September 25, 2018 by and between Dominion Capital LLC (the “Holder”) and DPW Holdings, Inc.,
a Delaware corporation (the “Company”).

 

 

Recitals

 

		A.	The Company has executed various documents concerning credit extended by the Holder, including,
without limitation, the Securities Purchase Agreement dated as of May 15, 2018 (the “May Agreement”), the Transaction
Documents (as defined in the May Agreement)) and, more specifically, the Senior Secured Convertible Promissory Note dated May 15,
2018 and originally due November 15, 2018 (the “May Note”), the Senior Secured Convertible Promissory Note dated
July 2, 2018 and due January 1, 2019 (the “July Note”) acquired pursuant to a Securities Purchase Agreement
dated as of July 2, 2018 and the Senior Secured Convertible Promissory Note dated September 2, 2018 (the “September Note”)
acquired pursuant to a Securities Purchase Agreement dated as of September 2, 2018, as such documents have been amended to date.

 

		B.	The Holder and the Company desire to further amend the May Note, the July Note, and the September
Note as set forth herein.

 

NOW, THEREFORE, for
TEN DOLLARS ($10.00) and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the
parties hereto, intending to be legally bound hereby, agree as follows:

 

1.     Definitions.
Capitalized terms used but not defined in this Amendment shall have the meaning given to them in the May Note, the July Note and
the September Note, as applicable, and the other Transaction Documents.

 

		2.	Amendments to May Note. The May Note, including its Notice of Conversion and Schedule, is
hereby amended as follows:

 

(a)       By
replacing Section 2(f), which currently provides (as modified by Amendment 6):

 

f)       Amortization.
Commencing on September 30, 2018 and continuing every month thereafter for a period of fourteen (14) months (each, an “Amortization
Payment Date”), the Company shall redeem one-fourteenth (1/14th) of each of the original principal amount of this Note,
accrued but unpaid interest in accordance with the Amortization Payment Schedule set forth on Schedule 2(f) (each, an “Amortization
Payment”). Each Amortization Payment shall be made in cash in the amounts set forth on Schedule 2(f) hereto. Any outstanding
unpaid principal and accrued interest on this Note as of the Maturity Date will be due and payable on the Maturity Date in cash.

 

And substituting in lieu thereof:

 

f)       Amortization.
Commencing on September 30, 2018 and continuing every month thereafter on the date provided for in Schedule 2(f) for a period of
fourteen (14) months (each, an “Amortization Payment Date”), the Company shall redeem the principal amount of
$309,192.71 plus accrued but unpaid interest of $41,924.43 for thirteen (13) payments and the principal amount of $1,011,426.83
plus accrued but unpaid interest of $41,924.43 for the fourteenth (14th) payment in accordance with the Amortization Payment Schedule
set forth on Schedule 2(f) (each, an “Amortization Payment”). Each Amortization Payment shall be made in cash
or Bitcoin in the amounts set forth on Schedule 2(f) hereto. Any outstanding unpaid principal and accrued interest on this Note
as of the Maturity Date will be due and payable on the Maturity Date in cash.

 

(b)       By
replacing the Amortization Payment Schedule in Section 2(f) of the Note with the Amortization Payment Schedule set forth on Exhibit
A hereto.

 

		3.	Amendments to May Note, July Note and the September Note. Each of the May Note, July Note
and September Note are hereby amended as follows:

 

By replacing
Section 2(e) in each of the May Note, July Note, September Note and all prior applicable amendments which currently provide for
varying treatment of mandatory prepayment upon a capital-raising event and substituting in lieu thereof: May
Note:

 

 

    	  

    	 

    

  

(e)       
 Mandatory Prepayment. During the term of the Note, (i) in the event that the
Company consummates any single or contemporaneous public or private offerings of securities in which the Company receives gross
proceeds in the aggregate equal to or greater than $2,000,000 (a “ Qualified Offering ”), excluding
investments from officers, directors and related entities, or (ii) in the event that the Company receives funds pursuant to a repayment
from a related party of promissory notes issued to such entity (each a “ Non-Qualified Offering ”),
at any time upon thirty (30) days written notice to the Holder, but subject to the Holder’s conversion rights set forth herein,
the Company shall make payment to the Holder , from up to 25% of the proceeds from such Qualified Offering or Non-Qualified Offering,
as applicable, of an amount in cash as follows: (w) the principal amount of the Note then outstanding plus (x) accrued and unpaid
guaranteed interest and the Make-Whole Amount on the outstanding principal amount to the date of mandatory prepayment (the “ Mandatory
Prepayment Date ”) plus (y) any other amounts due under the Note, including Late Fees, if any, on the amounts referred
to in clauses (w) and (x).

 

For
the avoidance of doubt and subject to the notice periods and payment terms outlined herein, any mandatory prepayment of the Company
to the Holder shall be applied first in the following order unless modified by the parties in writing:

 

First,
mandatory prepayment of the Senior Secured Convertible Promissory Note, dated July 2, 2018 (as amended, the “July Note”),
on the terms therein;

 

Second,
mandatory prepayment of the Senior Secured Convertible Promissory Note, dated September 2, 2018 (as amended, the “September
Note”), on the terms therein; and

 

Lastly,
mandatory prepayment of this Note.

 

Under
no circumstance shall the Company be obligated to pay the applicable mandatory prepayment with respect to more than one of this
Note or the July or September Notes in connection with any Qualified Offering or Non-Qualified Offering; for example, there shall
be no requirement to make a mandatory prepayment on the September Note or this Note until the entirety of the outstanding principal
amount and accrued but unpaid interest on the July Note shall have been repaid and such July Note shall have been cancelled upon
repayment.

 

July
and September Notes:

 

(e)       
 Mandatory Prepayment. During the term of the Note, (i) in the event that the
Company consummates any single or contemporaneous public or private offerings of securities in which the Company receives gross
proceeds in the aggregate equal to or greater than $2,000,000 (a “ Qualified Offering ”), excluding
investments from officers, directors and related entities, or (ii) in the event that the Company receives funds pursuant to a repayment
from a related party of promissory notes issued to such entity (each a “ Non-Qualified Offering ”),
at any time upon thirty (30) days written notice to the Holder, but subject to the Holder’s conversion rights set forth herein,
the Company shall make payment to the Holder, from up to 25% of the proceeds from such Qualified Offering or Non-Qualified Offering,
as applicable, of an amount in cash as follows:

 

(A)
if the Company is required to prepay the Note at any time within the initial thirty (30) days following the Original Issue Date,
the Company shall make payment to the Holder of an amount in cash equal to the sum of: (w) 105% multiplied by the principal amount
of the Note then outstanding plus (x) accrued and unpaid guaranteed interest on the outstanding principal amount to the date of
mandatory prepayment (the “Mandatory Prepayment Date ”) plus (y) any other amounts due under the Note,
including Late Fees, if any, on the amounts referred to in clauses (w) and (x); (B) if the Company is required to prepay the Note
at any time from the 31st day through the 60th day following the Original Issue Date, the Company shall make payment to the Holder
of an amount in cash equal to the sum of: (w) 110% multiplied by the principal amount of the Note then outstanding plus (x) accrued
and unpaid guaranteed interest on the principal amount to the Mandatory Prepayment Date plus (y) any other amounts due under the
Note, including Late Fees, if any, on the amounts referred to in clauses (w) and (x); (C) if the Company is required to prepay
the Note at any time from the 61st day through the 90th day following the Original Issue Date, the Company shall make payment to
the Holder of an amount in cash equal to the sum of: (w) 115% multiplied by the principal amount of the Note then outstanding plus
(x) accrued and unpaid guaranteed interest on the principal amount to the Mandatory Prepayment Date plus (y) any other amounts
due under the Note, including Late Fees, if any, on the amounts referred to in clauses (w) and (x); (D) if the Company is required
to prepay the Note at any time from the 91st day through the 120th day following the Original Issue Date, the Company shall make
payment to the Holder of an amount in cash equal to the sum of: (w) 120% multiplied by the principal amount of the Note then outstanding
plus (x) accrued and unpaid guaranteed interest on the principal amount to the Mandatory Prepayment Date plus (y) any other amounts
due under the Note, including Late Fees, if any, on the amounts referred to in clauses (w) and (x); and (E) if the Company is required
to prepay the Note at any time from the 121st day through the Maturity Date, the Company shall make payment to the Holder of an
amount in cash equal to the sum of: (w) 125% multiplied by the principal amount of the Note then outstanding plus (x) accrued and
unpaid guaranteed interest on the principal amount of the Note to the Mandatory Prepayment Date plus (y) any other amounts due
under the Note, including Late Fees, if any, on the amounts referred to in clauses (w) and (x). The Holder may continue to convert
the Note from the date notice of the mandatory prepayment is given until the date of the mandatory prepayment.

 

    	- 2 -

    	 

    

 

For
the avoidance of doubt and subject to the notice periods and payment terms outlined herein, any mandatory prepayments of the Company
to the Holder shall be applied first in the following order unless modified by the parties in writing:

 

First,
mandatory prepayment of the Senior Secured Convertible Promissory Note, dated July 2, 2018 (as amended, the “July Note”),
on the terms therein;

 

Second,
mandatory prepayment of the Senior Secured Convertible Promissory Note, dated September 2, 2018 (as amended, the “September
Note”), on the terms therein; and

 

Lastly,
mandatory prepayment of the Senior Secured Convertible Promissory Note, dated May 15, 2018 (as amended, the “May Note”),
on the terms therein.

 

Under
no circumstance shall the Company be obligated to pay the applicable mandatory prepayment with respect to more than one of the
May, July or September Notes in connection with any Qualified Offering or Non-Qualified Offering; for example, there shall be no
requirement to make a mandatory prepayment on the September Note or the May Note until the entirety of the outstanding principal
and accrued but unpaid interest of the July Note shall have been repaid and such July Note shall have been cancelled upon repayment.

 

4.       Representations
and Warranties. When the Company signs this Amendment, the Company represents and warrants to the Holder that: (a) this Amendment
is within the Company’s powers, has been duly authorized, does not conflict with any of the Company’s organizational
papers and is the legal, valid and binding obligation of the Company enforceable against it in accordance with its terms, and (b)
that the person or persons executing this Amendment on behalf of the Company are duly appointed officers or other representatives
of the Company with authority to execute and deliver this Amendment on behalf of the Company.

 

5.       Conditions.
This Amendment will be effective when all of the following conditions shall have been satisfied, as determined by the Holder in
its sole discretion and the Holder shall have accepted this Amendment (notice of which acceptance is hereby waived by the Company).

 

		a.	The Holder has received evidence that the execution, delivery and performance by the Company of
this Amendment and any instrument or agreement required under this Amendment have been duly authorized.

 

		b.	This Amendment has been executed by the Company and the Holder.

 

		c.	The Company has filed with the SEC an amendment to the current registration statement on Form S-3
(File No. 333-226301) (the “Registration Statement”) to register the shares of Common Stock underlying the May and
July Notes and the 400,000 shares of Common Stock due to the Holder pursuant to Amendment No. 3 Agreement, dated July 2 2018, between
the Company and the Holder. The Company expressly acknowledges that the 8,000,000 shares of Common Stock underlying the May and
July Notes and the 400,000 shares of Common Stock can be issued via DWAC without a restrictive legend once the Registration Statement
is declared effective and shall be eligible to trade on the NYSE American exchange. For the avoidance of doubt, if the Company
does not use its commercially reasonable best efforts to cause the Registration Statement to be declared effective within thirty
(30) days of the date of this Amendment, then this condition 5(c) shall retroactively be determined not to have been met and this
Amendment will be of no further force and effect.

 

6.       Effect
of Amendment; References.

 

		a.	Except as expressly amended hereby, all of the terms and conditions of the May Note, the July Note
and the September Note shall remain unchanged and in full force and effect and the Company hereby reaffirms its obligations under
the May Note, the July Note and the September Note, as amended by this Amendment, without defense, right of set off or recoupment,
claim or counterclaim of any kind or nature (and to the extent there exists any such defense, right of set off or recoupment, claim
or counterclaim on the date hereof, the same is hereby forever released, discharged and waived by the Company). The Company hereby
reaffirms as of the date hereof its representations and warranties under each of the Transaction Documents.

 

    	- 3 -

    	 

    

 

		b.	This Amendment (i) is limited precisely as specified herein and does not constitute nor shall be
deemed to constitute a modification, acceptance or waiver of any other provision of the May Note, the July Note and the September
Note, (ii) is not intended to be, nor shall it be construed to create, a novation or an accord and satisfaction of any obligation
or liability of the Company under the May Note, the July Note and the September Note, and (iii) shall not prejudice or be deemed
to prejudice any rights or remedies the Holder may now have or may in the future have under or in connection with the May Note,
the July Note and the September Note.

 

		c.	All references in any Transaction Document to any other Transaction Document amended hereby shall
be deemed to be a reference to such Transaction Document as amended by this Amendment, if and as applicable.

 

8.             Miscellaneous.

 

		a.	This Amendment shall be governed by and construed in accordance with the laws of the state provided
in the May Agreement.

 

		b.	This Amendment may be executed in counterparts, each of which when so executed shall be deemed
an original, but all such counterparts together shall constitute but one and the same instrument. Delivery of an executed signature
page of this Amendment by facsimile or electronic transmission shall be effective as a delivery of a manually executed counterpart
thereof.

 

 

[Remainder of page intentionally blank.]

 

    	- 4 -

    	 

    

  

IN WITNESS WHEREOF,
the parties hereto have caused this Amendment to be duly executed under seal and delivered by their respective duly authorized
representatives on the date first written above.

 

 

	 	
        DPW HOLDINGS, INC.

         

	 	
        By:             /s/ Milton C, Ault III

        Name: Milton C. Ault
        III

        Title: Chief Executive
        Officer

         

        Facsimile No. for delivery of Notices:

 

 

 

	 	
        DOMINION CAPITAL, LLC

         

	 	
        By:             /s/ Mikhail Gurevich

        Name: Mikhail Gurevich

                Title:
        Managing Member, Dominion Capital Holdings LLC as 

  Managing Member of Dominion Capital LLC

         

        Facsimile No. for delivery of Notices:

 

    	- 5 -

    	 

    

  

Exhibit A 

 

Amortization Payment
Schedule (Updated)

 

 

 

Date Payment Number
Principal Amount Principal Payment Interest Payment Total Payment Due Cash Total Due in Bitcoin 8/31/2018 $ 5,030,932.06 9/30/2018
1 $ 309,192.71 $ 41,924.43 $ 351,117.14 $ 386,228.86 10/31/2018 2 $ 309,192.71 $ 41,924.43 $ 351,117.14 $ 386,228.86 11/30/2018
3 $ 309,192.71 $ 41,924.43 $ 351,117.14 $ 386,228.86 12/31/2018 4 $ 309,192.71 $ 41,924.43 $ 351,117.14 $ 386,228.86 1/31/2019
5 $ 309,192.71 $ 41,924.43 $ 351,117.14 $ 386,228.86 2 /28/2019 6 $ 309,192.71 $ 41,924.43 $ 351,117.14 $ 386,228.86 3/31/2019
7 $ 309,192.71 $ 41,924.43 $ 351,117.14 $ 386,228.86 4 /30/2019 8 $ 309,192.71 $ 41,924.43 $ 351,117.14 $ 386,228.86 5/31/2019
9 $ 309,192.71 $ 41,924.43 $ 351,117.14 $ 386,228.86 6 /30/2019 10 $ 309,192.71 $ 41,924.43 $ 351,117.14 $ 386,228.86 7/31/2019
11 $ 309,192.71 $ 41,924.43 $ 351,117.14 $ 386,228.86 8/31/2019 12 $ 309,192.71 $ 41,924.43 $ 351,117.14 $ 386,228.86 9 /30/2019
13 $ 309,192.71 $ 41,924.43 $ 351,117.14 $ 386,228.86 10/31/2019 14 $ 1,011,426.83 $ 41,924.43 $ 1,053,351.26 $ 1,158,686.39

 

- 6 -EX-4.2

 Exhibit 4.2 

Execution Version 

INVESTORS’ RIGHTS AGREEMENT 

THIS INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the
19th day of June, 2017, by and among LogicBio Therapeutics Inc., a Delaware corporation (the “Company”), each of the holders of Preferred Stock of the Company listed on Schedule A
hereto, each of which is referred to in this Agreement as an “Investor”, and each of the holders of Common Stock of the Company listed on Schedule B hereto, each of whom is referred to herein as a “Common
Holder” and any additional parties that become a party to this Agreement in accordance with Section 6.9 or Section 6.9 hereof. 

WHEREAS, the Investors are parties to that certain Series B Preferred Stock Purchase Agreement of even date herewith between the
Company and the Investors (the “Purchase Agreement”), under which certain of the Company’s and such Investors’ obligations are conditioned upon the execution and delivery of this Agreement by such Investors, the Company
and the Common Holders; 
 NOW, THEREFORE, the parties to this Agreement further agree as follows: 

1. Definitions. For purposes of this Agreement: 

1.1. “Affiliate” means, with respect to any specified Person, any other Person who, directly or indirectly, controls, is
controlled by, or is under common control with such Person, including without limitation any general partner, managing member, officer or director of such Person or any venture capital fund now or hereafter existing that is controlled by one or more
general partners or managing members of, or shares the same management company with, such Person. 
 1.2. “Certificate of
Incorporation” means the Company’s Certificate of Incorporation, as amended and in effect from time to time. 
 1.3.
“Common Holder Registrable Securities” means (i) the shares of Common Stock held by the Common Holders, and (ii) any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other
security that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of such shares. 
 1.4.
“Common Stock” means shares of the Company’s common stock, par value $0.0001 per share. 
 1.5.
“Damages” means any loss, damage, claim or liability (joint or several) to which a party hereto may become subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or
liability (or any action in respect thereof) arises out of or is based upon: (i) any untrue statement or alleged untrue statement of a material fact contained in any registration statement of the Company, including any preliminary prospectus or
final prospectus contained therein or any amendments or supplements thereto; (ii) an omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or
(iii) any violation or alleged violation by the indemnifying party (or any of its agents or Affiliates) of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities
Act, the Exchange Act, or any state securities law. 
 1.6. “Derivative Securities” means any securities or rights
convertible into, or exercisable or exchangeable for (in each case, directly or indirectly), Common Stock, including options and warrants. 

  
 1 

 1.7. “Exchange Act” means the Securities Exchange Act of
1934, as amended, and the rules and regulations promulgated thereunder. 
 1.8. “Excluded Registration” means
(i) a registration relating to the sale of securities to employees of the Company or a subsidiary pursuant to a stock option, stock purchase, or similar plan; (ii) a registration relating to an SEC Rule 145 transaction; (iii) a
registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities; or (iv) a registration in which the only Common
Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered.  
 1.9.
“Form S-1” means such form under the Securities Act as in effect on the date hereof or any successor registration form under the Securities Act subsequently adopted by the
SEC.  
 1.10. “Form S-3” means such form under the Securities
Act as in effect on the date hereof or any registration form under the Securities Act subsequently adopted by the SEC that permits incorporation of substantial information by reference to other documents filed by the Company with the SEC. 

1.11. “GAAP” means generally accepted accounting principles in the United States. 

1.12. “Holder” means any holder of Registrable Securities who is a party to this Agreement. 

1.13. “Immediate Family Member” means a child, stepchild grandchild, parent, stepparent, grandparent, spouse, sibling,
mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law,
or sister-in-law, including, adoptive relationships, of a natural person referred to herein. 

1.14. “Initiating Holders” means, collectively, Holders who properly initiate a registration request under this
Agreement. 
 1.15. “IPO” means the Company’s first underwritten public offering of its Common Stock under the
Securities Act. 
 1.16. “Major Investor” means any Investor that, individually or together with such
Investor’s Affiliates, holds at least 5% of the issued and outstanding capital stock of the Company on an as converted to Common Stock basis. 

1.17. “New Securities” means, collectively, equity securities of the Company, whether or not currently
authorized, as well as rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable for such equity securities. 

1.18. “Person” means any individual, corporation, partnership, trust, limited liability company, association or other entity.

 1.19. “Preferred Stock” means shares of Series A Preferred Stock and Series B Preferred Stock. 

1.20. “Previous Agreement” that certain Investors’ Rights Agreement dated as of the January 13, 2016 by and
among the Company and certain of its stockholders. 

  
 2 

 1.21. “Qualified IPO” has the meaning set forth in the
Certificate of Incorporation. 
 1.22. “Registrable Securities” means (i) the Common Stock issuable or issued
upon conversion of the Preferred Stock; (ii) any Common Stock, or any Common Stock issued or issuable (directly or indirectly) upon conversion and/or exercise of any other securities of the Company,
acquired by the Investors after the date hereof; (iii) the Common Holder Registrable Securities, provided, however, that such Common Holder Registrable Securities shall not be deemed Registrable Securities and the Common Holders shall
not be deemed Holders for the purposes of Sections 2.1, 2.2, 2.3 and 2.10; and (iv) any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or other
distribution with respect to, or in exchange for or in replacement of, the shares referenced in clauses (i) and (ii) above; excluding in all cases, however, any Registrable Securities sold by a Person in a transaction in which the applicable
rights under this Agreement are not assigned pursuant to Section 6.1, and excluding for purposes of Section 2 any shares for which registration rights have terminated pursuant to Section 2.13 of this Agreement. 

1.23. “Restricted Securities” means the securities of the Company required to be notated with the legend set
forth in Section 2.12(b) hereof. 
 1.24. “SEC” means the Securities and Exchange Commission. 

1.25. “SEC Rule 144” means Rule 144 promulgated by the SEC under the Securities Act. 

1.26. “SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities Act. 

1.27. “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated
thereunder. 
 1.28. “Selling Expenses” means all underwriting discounts, selling commissions, and stock
transfer taxes applicable to the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel (as defined below) borne and paid by the Company as provided
in Section 2.6. 
 1.29. “Series A Preferred Stock” means shares of the Company’s Series A
Preferred Stock, par value $0.0001 per share. 
 1.30. “Series B Preferred Stock” means shares of the
Company’s Series B Preferred Stock, par value $0.0001 per share. 
 1.31. “Voting Agreement” means that
certain Voting Agreement of even date herewith between the Company, the Investors and the other parties named therein. 
 2. Registration
Rights. The Company covenants and agrees as follows: 
 2.1. Demand Registration. 

(a) Form S-1 Demand. If at any time after the earlier of (i) five (5) years after the
date of this Agreement or (ii) one hundred eighty (180) days after the effective date of the registration statement for the IPO, the Company receives a request from Holders of at least sixty percent (60%) of the Registrable Securities then
outstanding that the Company file a Form S-1 registration 

  
 3 

 
statement, then the Company shall (x) within ten (10) days after the date such request is given, give notice thereof (the “Demand Notice”) to all Holders
other than the Initiating Holders; and (y) as soon as practicable, and in any event within sixty (60) days after the date such request is given by the Initiating Holders, file a Form S-1 registration
statement under the Securities Act covering all Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable Securities requested to be included in such registration by any other Holders, as
specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Sections 2.1(c) and 2.3. 

(b) Form S-3 Demand. If at any time when it is eligible to use a Form S-3 registration statement, the Company receives a request from a Holder or Holders that the Company file a Form S-3 registration statement with respect to outstanding
Registrable Securities of such Holders having an anticipated aggregate offering price, net of Selling Expenses, of at least $1 million, then the Company shall (i) within ten (10) days after the date such request is given, give a
Demand Notice to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within forty-five (45) days after the date such request is given by the Initiating Holders, file a Form S-3 registration statement under the Securities Act covering all Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the
Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Sections 2.1(c) and 2.3.  

(c) Notwithstanding the foregoing obligations, if the Company furnishes to Holders requesting a registration pursuant to this
Section 2.1 a certificate signed by the Company’s chief executive officer stating that in the good faith judgment of the Company’s Board of Directors (the “Board”) it would be materially detrimental to the
Company and its stockholders for such registration statement to either become effective or remain effective for as long as such registration statement otherwise would be required to remain effective, because such action would (i) materially
interfere with a significant acquisition, corporate reorganization, or other similar transaction involving the Company; (ii) require premature disclosure of material information that the Company has a bona fide business purpose for preserving
as confidential; or (iii) render the Company unable to comply with requirements under the Securities Act or Exchange Act, then the Company shall have the right to defer taking action with respect to such filing for a period of no longer than
ninety (90) days after the request by the Initiating Holders is given; provided, however, that the Company may not invoke this right more than once in any twelve (12) month period; and provided further that the
Company shall not register any securities for its own account or that of any other stockholder during such ninety (90) day period. 

(d) The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Section 2.1(a)(i) during
the period that is sixty (60) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is one hundred and eighty (180) days after the effective date of, a Company-initiated registration,
provided that the Company is actively employing good faith commercially reasonable efforts to cause such registration statement to become effective; (ii) after the Company has effected two registrations pursuant to Section 2.1(a);
or (iii) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to Section 2.1(b). The
Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Section 2.1(b) during the period that is thirty (30) days before the Company’s good faith estimate of the date of filing of, and
ending on a date that is ninety (90) days after the effective date of, a Company-initiated registration, provided that the Company is actively employing good faith commercially reasonable efforts to cause such registration statement to
become effective. A registration shall not be counted as “effected” for purposes of this Section 2.1(d) until such time as the applicable registration statement has been declared effective by the SEC, unless the Initiating Holders
withdraw their request for such registration, elect not to pay the registration expenses therefor, and forfeit their right to one demand registration statement pursuant to Section 2.6, in which case such withdrawn registration statement shall
be counted as “effected” for purposes of this Section 2.1(d). 

  
 4 

 2.2. Company Registration. If the Company proposes to register (including, for this
purpose, a registration effected by the Company for stockholders other than the Holders) any of its Common Stock under the Securities Act in connection with the public offering of such securities solely for cash (other than in an Excluded
Registration), the Company shall, at such time, promptly give each Holder notice of such registration. Upon the request of each Holder given within twenty (20) days after such notice is given by the Company, the Company shall, subject to the
provisions of Section 2.3, cause to be registered all of the Registrable Securities that each such Holder has requested to be included in such registration. The Company shall have the right to terminate or withdraw any registration initiated by
it under this Section 2.2 before the effective date of such registration, whether or not any Holder has elected to include Registrable Securities in such registration. The expenses (other than Selling Expenses) of such withdrawn registration
shall be borne by the Company in accordance with Section 2.6. 
 2.3. Underwriting Requirements. 

(a) If, pursuant to Section 2.1, the Initiating Holders intend to distribute the Registrable Securities covered by their request by
means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Subsection 2.1, and the Company shall include such information in the Demand Notice. The underwriter(s) will be selected by the Initiating
Holders, subject to the approval of the Company not to be unreasonably withheld. In such event, the right of any Holder to include such Holder’s Registrable Securities in such registration shall be conditioned upon such Holder’s
participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall (together with
the Company as provided in Subsection 2.4(e)) enter into an underwriting agreement in customary form with the underwriter(s) selected for such underwriting. Notwithstanding any other provision of this Subsection 2.3, if the underwriter(s) advise(s)
the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, then the Initiating Holders shall so advise all Holders of Registrable Securities that otherwise would be underwritten pursuant
hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated among such Holders of Registrable Securities, including the Initiating Holders, in proportion (as nearly as practicable) to the number of
Registrable Securities owned by each Holder or in such other proportion as shall mutually be agreed to by all such selling Holders; provided, however, that the number of Registrable Securities held by the Holders to be included in such underwriting
shall not be reduced unless all other securities are first entirely excluded from the underwriting. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares
allocated to any Holder to the nearest one hundred (100) shares. 
 (b) In connection with any offering involving an underwriting of
shares of the Company’s capital stock pursuant to Section 2.2, the Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting unless the Holders accept the terms of the underwriting as
agreed upon between the Company and its underwriters, and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number of securities, including
Registrable Securities, requested by stockholders to be included in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success
of the offering, then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion 

  
 5 

 determine will not jeopardize the success of the offering. If the underwriters determine that less than all
of the Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities that are included in such offering shall be allocated among the selling Holders in proportion (as nearly as practicable) to
the number of Registrable Securities owned by each selling Holder or in such other proportions as shall mutually be agreed to by all such selling Holders. To facilitate the allocation of shares in accordance with the above provisions, the Company or
the underwriters may round the number of shares allocated to any Holder to the nearest one hundred (100) shares. Notwithstanding the foregoing, in no event shall (i) the number of Registrable Securities included in the offering be reduced
unless all other securities (other than securities to be sold by the Company) are first entirely excluded from the offering, (ii) the number of Registrable Securities included in the offering be reduced below twenty five percent (25%) of the
total number of securities included in such offering, unless such offering is the IPO, in which case the selling Holders may be excluded further if the underwriters make the determination described above and no other stockholder’s securities
are included in such offering or (iii) notwithstanding (ii) above, any Registrable Securities which are not Common Holder Registrable Securities be excluded from such underwriting unless all Common Holder Registrable Securities are first
excluded from such offering. For purposes of the provision in this Subsection 2.3(b) concerning apportionment, for any selling Holder that is a partnership, limited liability company, or corporation, the partners, members, retired partners, retired
members, stockholders, and Affiliates of such Holder, or the estates and Immediate Family Members of any such partners, retired partners, members, and retired members and any trusts for the benefit of any of the foregoing Persons, shall be deemed to
be a single “selling Holder,” and any pro rata reduction with respect to such “selling Holder” shall be based upon the aggregate number of Registrable Securities owned by all Persons included in such “selling Holder,”
as defined in this sentence. 
 (c) For purposes of Section 2.1, a registration shall not be counted as “effected” if, as a
result of an exercise of the underwriter’s cutback provisions in Section 2.3(a), fewer than fifty percent (50%) of the total number of Registrable Securities that Holders have requested to be included in such registration statement are
actually included. 
 2.4. Obligations of the Company. Whenever required under this Section 2 to effect the registration of any
Registrable Securities, the Company shall, as expeditiously as reasonably possible: 
 (a) prepare and file with the SEC a registration
statement with respect to such Registrable Securities and use its commercially reasonable efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities registered
thereunder, keep such registration statement effective for a period of up to one hundred twenty (120) days or, if earlier, until the distribution contemplated in the registration statement has been completed; provided, however,
that (i) such one hundred twenty (120) day period shall be extended for a period of time equal to the period the Holder refrains, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any
securities included in such registration, and (ii) in the case of any registration of Registrable Securities on Form S-3 that are intended to be offered on a continuous or delayed basis, subject to
compliance with applicable SEC rules, such one hundred twenty (120) day period shall be extended for up to an additional one hundred twenty (120) days, if necessary, to keep the registration statement effective until all such Registrable
Securities are sold; 
 (b) prepare and file with the SEC such amendments and supplements to such registration statement, and the prospectus
used in connection with such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such registration statement; 

  
 6 

 (c) furnish to the selling Holders such numbers of copies of a prospectus, including a
preliminary prospectus, as required by the Securities Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; 

(d) use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other
securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall not be required to qualify to do business or to file a general
consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

(e) in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and
customary form, with the underwriter(s) of such offering; 
 (f) use its commercially reasonable best efforts to cause all such Registrable
Securities covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued by the Company are then listed; 

(g) provide a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and provide a CUSIP number
for all such Registrable Securities, in each case not later than the effective date of such registration; 
 (h) promptly make available
for inspection by the selling Holders, any managing underwriter(s) participating in any disposition pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling
Holders, all financial and other records, pertinent corporate documents, and properties of the Company, and cause the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any
such seller, underwriter, attorney, accountant, or agent, in each case, as necessary or advisable to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith; 

(i) notify each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has been
declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and 
 (j) after such
registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or supplement such registration statement or prospectus. 

In addition, the Company shall ensure that, at all times after any registration statement covering a public offering of securities of the
Company under the Securities Act shall have become effective, its insider trading policy shall provide that the Company’s directors may implement a trading program under Rule 10b5-1 of the Exchange Act.

 2.5. Furnish Information. It shall be a condition precedent to the obligations of the Company to take any action pursuant to this
Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable Securities held by it, and the intended method of disposition of such
securities as is reasonably required to effect the registration of such Holder’s Registrable Securities. 

  
 7 

 2.6. Expenses of Registration. All expenses (other than Selling Expenses) incurred in
connection with registrations, filings, or qualifications pursuant to Section 2, including all registration, filing, and qualification fees; printers’ and accounting fees; fees and disbursements of counsel for the Company; and the
reasonable fees and disbursements of one counsel for the selling Holders (“Selling Holder Counsel”), shall be borne and paid by the Company; provided, however, that the Company shall not be required to
pay for any expenses of any registration proceeding begun pursuant to Section 2.1 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered (in which case
all selling Holders shall bear such expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn registration), unless the Holders of at least sixty percent (60%) of the Registrable Securities agree to
forfeit their right to one registration pursuant to Sections 2.1(a) or 2.1(b), as the case may be; provided further that if, at the time of such withdrawal, the Holders shall have learned of a material adverse change in the condition, business, or
prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request with reasonable promptness after learning of such information then the Holders shall not be required to pay any of such expenses and
shall not forfeit their right to one registration pursuant to Sections 2.1(a) or 2.1(b). All Selling Expenses relating to Registrable Securities registered pursuant to this Section 2 shall be borne and paid by the Holders pro rata on the basis
of the number of Registrable Securities registered on their behalf. 
 2.7. Delay of Registration. No Holder shall have any right to
obtain or seek an injunction restraining or otherwise delaying any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2. 

2.8. Indemnification. If any Registrable Securities are included in a registration statement under this Section 2: 

(a) To the extent permitted by law, the Company will indemnify and hold harmless each selling Holder, and the partners, members, officers,
directors, and stockholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the Securities Act) for each such Holder; and each Person, if any, who controls such Holder or underwriter within the
meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other aforementioned Person any legal or other expenses reasonably incurred thereby in
connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Section 2.8(a) shall not apply to
amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld, nor shall the Company be liable for any Damages to the extent that they
arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any such Holder, underwriter, controlling Person, or other aforementioned Person expressly for use in
connection with such registration. 
 (b) To the extent permitted by law, each selling Holder, severally and not jointly, will indemnify
and hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within the meaning of the Securities Act, legal counsel and accountants for the
Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other Holder, against any Damages, in each case only to the extent
that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling Holder expressly for use in connection with such registration; and each
such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with 

  
 8 

 investigating or defending any claim or proceeding from which Damages may result, as such expenses are
incurred; provided, however, that the indemnity agreement contained in this Section 2.8(b) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the
Holder, which consent shall not be unreasonably withheld; and provided further that in no event shall the aggregate amounts payable by any Holder by way of indemnity or contribution under Sections 2.8(b) and 2.8(d) exceed the proceeds from the
offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful misconduct by such Holder. 

(c) Promptly after receipt by an indemnified party under this Section 2.8 of notice of the commencement of any action (including
any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Section 2.8, give the indemnifying party
notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so desires, participate jointly with any other indemnifying party to which notice has been given,
and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified parties that may be represented without conflict by one counsel)
shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual
or potential differing interests between such indemnified party and any other party represented by such counsel in such action. The failure to give notice to the indemnifying party within a reasonable time of the commencement of any such action
shall relieve such indemnifying party of any liability to the indemnified party under this Section 2.8, to the extent that such failure materially prejudices the indemnifying party’s ability to defend such action. The failure to give
notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Section 2.8. 

(d) To provide for just and equitable contribution to joint liability under the Securities Act in any case in which either: (i) any
party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Section 2.8 but it is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the
expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this Section 2.8 provides for indemnification in such case, or
(ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this Section 2.8, then, and in each such case, such parties will contribute to the aggregate losses,
claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party in connection with
the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified
party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission of a material fact, relates to information supplied by the indemnifying party or
by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission; provided, however, that, in any such case (x) no Holder will be
required to contribute any amount in excess of the public offering price of all such Registrable Securities offered and sold by such Holder pursuant to such registration statement, and (y) no Person guilty of fraudulent misrepresentation
(within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation; and provided further that in no event shall a Holder’s
liability pursuant to this Section 2.8(d), when combined with the amounts paid or payable by such Holder pursuant to Section 2.8(b), exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such
Holder), except in the case of willful misconduct or fraud by such Holder. 

  
 9 

 (e) Notwithstanding the foregoing, to the extent that the provisions on indemnification and
contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 

(f) Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering, the
obligations of the Company and Holders under this Section 2.8 shall survive the completion of any offering of Registrable Securities in a registration under this Section 2, and otherwise shall survive the termination of this Agreement.

 2.9. Reports Under Exchange Act. With a view to making available to the Holders the benefits of SEC Rule 144 and any other rule or
regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form S-3, the Company shall: 

(a) make and keep available adequate current public information, as those terms are understood and defined in SEC Rule 144, at all times
after the effective date of the registration statement filed by the Company for the IPO; 
 (b) use commercially reasonable best efforts to
file with the SEC in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and 

(c) furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to the extent accurate, a
written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90) days after the effective date of the registration statement filed by the Company for the IPO), the Securities
Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any
time after the Company so qualifies); (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company; and (iii) such other information as may be reasonably requested in
availing any Holder of any rule or regulation of the SEC that permits the selling of any such securities without registration (at any time after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form
S-3 (at any time after the Company so qualifies to use such form). 
 2.10. Limitations on
Subsequent Registration Rights. From and after the date of this Agreement, the Company shall not, without the prior written consent of the Holders of a majority of the Registrable Securities then outstanding, enter into any agreement with any
holder or prospective holder of any securities of the Company that would grant any holder or prospective holder of any securities of the Company registration rights with respect to such securities; provided that this limitation shall not
apply to any additional Investor who becomes a party to this Agreement in accordance with Section 6.9. 
 2.11. “Market Stand-off” Agreement. Each Holder (including, without limitation each Common Holder) hereby agrees that it will not, without the prior written consent of the managing underwriter, during the period
commencing on the date of the final prospectus relating to the registration by the Company of shares of its Common Stock or any other equity securities under the Securities Act on a registration statement on Form S-1 or Form S-3, and ending on the date specified by the Company and the managing underwriter (such period not to exceed one hundred eighty (180) days in the case of the
IPO, or ninety (90) days in the case of any registration other than the IPO, or such other period as may be requested by the Company or an underwriter to accommodate regulatory restrictions on (1) the 

  
 10 

 publication or other distribution of research reports and (2) analyst recommendations and opinions,
including, but not limited to, the restrictions contained in FINRA Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or amendments thereto) (i) lend; offer; pledge; sell; contract to sell; sell any option or contract to
purchase; purchase any option or contract to sell; grant any option, right, or warrant to purchase; or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or
exchangeable (directly or indirectly) for Common Stock held immediately before the effective date of the registration statement for such offering or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part,
any of the economic consequences of ownership of such securities, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or other securities, in cash, or otherwise. The foregoing
provisions of this Section 2.11 shall not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement, and shall be applicable to the Holders only if all officers and directors and all stockholders
individually owning more than one percent (1%) of the Company’s outstanding Common Stock (after giving effect to conversion into Common Stock of all outstanding Preferred Stock) are subject to the same restrictions. The underwriters in
connection with such registration are intended third-party beneficiaries of this Section 2.11 and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. Each Holder further agrees to
execute such agreements as may be reasonably requested by the underwriters in connection with such registration that are consistent with this Section 2.11 or that are necessary to give further effect thereto. 

2.12. Restrictions on Transfer. 

(a) The Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise transferred, and the Company shall not
recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure compliance with the
provisions of the Securities Act. A transferring Holder will cause any proposed purchaser, pledgee, or transferee of the Preferred Stock and the Registrable Securities held by such Holder to agree to take and hold such securities subject to the
provisions and upon the conditions specified in this Agreement. 
 (b) Each certificate, instrument, or book entry representing
(i) the Preferred Stock, (ii) the Registrable Securities, and (iii) any other securities issued in respect of the securities referenced in clauses (i) and (ii), upon any stock split, stock dividend, recapitalization, merger,
consolidation, or similar event, shall (unless otherwise permitted by the provisions of Section 2.12(c)) be notated with a legend substantially in the following form: 

THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SHARES
MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. 

THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER,
A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY. 
 The Holders consent to the Company making a notation in its records and
giving instructions to any transfer agent of the Restricted Securities in order to implement the restrictions on transfer set forth in this Section 2.12. 

  
 11 

 (c) The holder of such Restricted Securities, by acceptance of ownership thereof, agrees to
comply in all respects with the provisions of this Section 2. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under the Securities Act covering the proposed
transaction, the Holder thereof shall give notice to the Company of such Holder’s intention to effect such sale, pledge, or transfer. Each such notice shall describe the manner and circumstances of the proposed sale, pledge, or transfer in
sufficient detail and, if reasonably requested by the Company, shall be accompanied at such Holder’s expense by either (i) a written opinion of legal counsel who shall, and whose legal opinion shall, be reasonably satisfactory to the
Company, addressed to the Company, to the effect that the proposed transaction may be effected without registration under the Securities Act; (ii) a “no action” letter from the SEC to the effect that the proposed sale, pledge, or
transfer of such Restricted Securities without registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any other evidence reasonably satisfactory to counsel to the Company to
the effect that the proposed sale, pledge, or transfer of the Restricted Securities may be effected without registration under the Securities Act, whereupon the Holder of such Restricted Securities shall be entitled to sell, pledge, or transfer such
Restricted Securities in accordance with the terms of the notice given by the Holder to the Company. The Company will not require such a legal opinion or “no action” letter (x) in any transaction in compliance with SEC Rule 144; or
(y) in any transaction in which such Holder distributes Restricted Securities to an Affiliate of such Holder for no consideration; provided that each transferee agrees in writing to be subject to the terms of this Section 2.12. Each
certificate, instrument, or book entry representing the Restricted Securities transferred as above provided shall be notated with, except if such transfer is made pursuant to SEC Rule 144, the appropriate restrictive legend set forth in
Section 2.12(b), except that such certificate instrument, or book entry shall not be notated with such restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is not required in order to establish
compliance with any provisions of the Securities Act. 
 2.13. Termination of Registration Rights. The right of any Holder to request
registration or inclusion of Registrable Securities in any registration pursuant to Sections 2.1 or 2.2 shall terminate upon the earliest to occur of: the closing of a Deemed Liquidation Event, as such term is defined in the Company’s
Certificate of Incorporation; or such time as Rule 144 or another similar exemption under the Securities Act is available for the sale of all of such Holder’s shares without limitation during a three-month period without registration;
and 
 2.14. Assignment of Registration Rights. Any of the Holders may assign its rights to cause the Company to register Registrable
Securities pursuant to this Section 2 (but only with all related obligations) only to a transferee or assignee of not less than 100,000 shares of Registrable Securities (as presently constituted and subject to subsequent adjustments for stock
splits, stock dividends, reverse stock splits and the like); provided that (i) the Company is given written notice prior to said transfer or assignment, stating the name and address of the transferee or assignee and identifying the
securities with respect to which such registration rights are intended to be transferred or assigned and (ii) the transferee or assignee of such rights assumes in writing the obligations of such Holder under this Agreement, including without
limitation the obligations set forth in Section 2. 
 3. Information Rights. 

3.1. Delivery of Financial Statements. The Company shall deliver to each Investor: 

(a) as soon as practicable after the end of each fiscal year of the Company, and in any event within ninety (90) days after the end of
each fiscal year of the Company, a consolidated balance sheet of the Company and its subsidiaries, if any, as at the end of such fiscal year, and consolidated statements of income and cash flows of the Company and its subsidiaries, if any, for such
year, prepared in accordance with U.S. GAAP consistently applied, all such financial statements audited and certified by one of the “Big Four” independent public accountants selected by the Company; 

  
 12 

 (b) as soon as practicable after the end of the first, second and third quarterly
accounting periods in each fiscal year of the Company, and in any event within forty-five (45) days after the end of the first, second, and third quarterly accounting periods in each fiscal year of the Company, an unaudited consolidated balance
sheet of the Company and its subsidiaries, if any, as of the end of each such quarterly period, and unaudited consolidated statements of income and cash flows of the Company and its subsidiaries, if any, for such period, prepared in accordance with
GAAP consistently applied, subject to changes resulting from normal year-end audit adjustments; 

(c) as soon as practicable, but in any event thirty (30) days before the end of each fiscal year, a budget and business and operating
plan for the next fiscal year (collectively, the “Budget”), approved by the Board and prepared on a monthly basis, including balance sheets, income statements, and statements of cash flow for such months and, promptly
after prepared, any other budgets or revised budgets prepared by the Company; and 
 (d) such other information relating to the financial
condition, business, prospects, or corporate affairs of the Company as any Investor may from time to time reasonably request; provided, however, that the Company shall not be obligated under this Section 3.1(d) to provide
information (i) that the Company reasonably determines in good faith to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in a form reasonably acceptable to the Company); or (ii) the
disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. 
 If, for any period, the
Company has any subsidiary whose accounts are consolidated with those of the Company, then in respect of such period the financial statements delivered pursuant to the foregoing sections shall be the consolidated financial statements of the Company
and all such consolidated subsidiaries. 
 Notwithstanding anything else in this Subsection 3.1 to the contrary, the Company may cease
providing the information set forth in this Subsection 3.1 during the period starting with the date sixty (60) days before the Company’s good-faith estimate of the date of filing of a registration statement if it reasonably concludes it
must do so to comply with the SEC rules applicable to such registration statement and related offering; provided that the Company’s covenants under this Subsection 3.1 shall be reinstated at such time as the Company is no longer actively
employing its commercially reasonable efforts to cause such registration statement to become effective. 
 3.2. Inspection. The
Company shall permit each Investor, at such Investor’s expense, to visit and inspect the Company’s properties; examine its books of account and records; and discuss the Company’s affairs, finances, and accounts with its officers,
during normal business hours of the Company as may be reasonably requested by the Investor; provided, however, that the Company shall not be obligated pursuant to this Section 3.2 to provide access to any information that it
reasonably and in good faith considers to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in form acceptable to the Company) or the disclosure of which would adversely affect the
attorney-client privilege between the Company and its counsel. 
 3.3. Termination of Information Rights. The covenants set forth in
Section 3.1 and Section 3.2 shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO or (ii) when the Company first becomes subject to the periodic reporting requirements of
Section 12(g) or 15(d) of the Exchange Act, or (iii) upon a Deemed Liquidation Event, as such term is defined in the Company’s Certificate of Incorporation, whichever event occurs first. 

  
 13 

 3.4. Observer Rights. As long as an Investor (a “Designating
Investor”) is entitled to designate an Investor Director (as defined in the Voting Agreement) under the Voting Agreement, the Company shall invite a representative of such Designating Investor to attend all meetings of the Board (in
addition to any Investor Director designated by the Designating Investor) in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its
directors at the same time and in the same manner as provided to such directors; provided, however, that such representative shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided;
and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting could adversely affect the
attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest, or if such Designating Investor or its representative is a competitor of the Company. Without limiting the foregoing,
Arix Bioscience, Inc. (“Arix”) initially designates Owen Smith as its representative to attend all meetings of the Board in a nonvoting observer capacity. Notwithstanding the foregoing, SBI JI Innovation Fund Limited
Partnership shall have the right to appoint a nonvoting observer to the Board under this Section 3.4. 
 3.5 Confidentiality.
Each Investor agrees that such Investor will keep confidential and will not disclose, divulge, or use for any purpose (other than to monitor its investment in the Company) any confidential information obtained from the Company pursuant to the terms
of this Agreement (including notice of the Company’s intention to file a registration statement), unless such confidential information (a) is known or becomes known to the public in general (other than as a result of a breach of this
Section 3.5 by such Investor), (b) is or has been independently developed or conceived by the Investor without use of the Company’s confidential information, or (c) is or has been made known or disclosed to the Investor by a third
party without a breach of any obligation of confidentiality such third party may have to the Company; provided, however, that an Investor may disclose confidential information (i) to its attorneys, accountants, consultants, and
other professionals to the extent necessary to obtain their services in connection with monitoring its investment in the Company; (ii) to any prospective purchaser of any Registrable Securities from such Investor, if such prospective purchaser
agrees to be bound by the provisions of this Section 3.5; (iii) to any existing or prospective Affiliate, partner, member, stockholder, or wholly owned subsidiary of such Investor in the ordinary course of business, provided that
such Investor informs such Person that such information is confidential and directs such Person to maintain the confidentiality of such information; or (iv) as may otherwise be required by law, provided that the Investor promptly
notifies the Company of such disclosure and takes reasonable steps to minimize the extent of any such required disclosure. 
 4. Rights
to Future Stock Issuances. 
 4.1. Right of First Offer. Subject to the terms and conditions of this Section 4.1 and
applicable securities laws, if the Company proposes to offer or sell any New Securities, the Company shall first offer such New Securities to each Major Investor. A Major Investor shall be entitled to apportion the rights of first offer hereby
granted to it in such proportions as it deems appropriate, among (i) itself, and (ii) its Affiliates; provided that each such Affiliate agrees to enter into this Agreement and the Voting Agreement, as an
“Investor” under each such agreement. 
 (a) The Company shall give notice (the “Offer
Notice”) to each Major Investor, stating (i) its bona fide intention to offer such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon which it proposes to
offer such New Securities. 

  
 14 

 (b) Each Major Investor shall have the right (such right being the “Right of First
Offer”), by giving notice to the Company no later than twenty (20) days after the Offer Notice is given, to elect to purchase or otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion
of such New Securities which equals the proportion that the Common Stock then held by such Major Investor (including all shares of Common Stock then issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred
Stock and any other Derivative Securities then held by such Major Investor) bears to the total Common Stock of the Company then held by all the Major Investors (including all shares of Common Stock issuable (directly or indirectly) upon conversion
and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held by the Major Investors). 
 (c)
At the expiration of twenty (20) day period after the Offer Notice is given, the Company shall promptly notify each Investor that elects to purchase or acquire all the shares available to it (each, a “Fully Exercising
Investor”) of any other Investor’s failure to do likewise. During the ten (10) day period commencing after the Company has given such notice, each Fully Exercising Investor shall have the right (such right being the
“Overallotment Right”), by giving notice to the Company, to elect to purchase or acquire, in addition to the number of shares specified in Section 3.4(b) above, up to that portion of the New Securities that were
not otherwise subscribed for by the Major Investors (such securities being the “Unsubscribed Securities”) which is equal to the proportion that the Common Stock issued and held, or issuable (directly or indirectly)
upon conversion and/or exercise, as applicable, of Preferred Stock and any other Derivative Securities then held, by such Fully Exercising Investor bears to the Common Stock issued and held, or issuable (directly or indirectly) upon conversion
and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held, by all Fully Exercising Investors who wish to purchase such unsubscribed shares. Notwithstanding the foregoing, holders of more than 50% of
the Preferred Stock may waive the Overallotment Right with respect to some or all of the Unsubscribed Securities. 
 (d) The closing of any
sale pursuant to Section 4.1(b) and Section 4.1(c) shall occur within the later of ninety (90) days of the date that the Offer Notice is given and the date of initial sale of New Securities pursuant to Section 4.1(e). 

(e) If all New Securities referred to in the Offer Notice are not elected to be purchased or acquired as provided in Section 4.1(b), the
Company may, upon resolution of the Board, during the ninety (90) day period following the expiration of the periods provided in Section 4.1(b), offer and sell the remaining unsubscribed portion of such New Securities to any Person or
Persons at a price not less than, and upon terms no more favorable to the offeree than, those specified in the Offer Notice. If the Company does not enter into an agreement for the sale of the New Securities within such period, or if such agreement
is not consummated within thirty (30) days of the execution thereof, the right provided hereunder shall be deemed to be revived and such New Securities shall not be offered unless first reoffered to the Major Investors in accordance with this
Section 4.1. 
 (f) The right of first offer in this Section 4.1 shall not be applicable to (i) Exempted Securities (as
defined in the Certificate of Incorporation); and (ii) shares of Common Stock issued in the IPO; and (iii) the issuance of shares of Series B Preferred Stock at Second Closing (as defined in the Purchase Agreement) pursuant to the
Purchase Agreement. 

  
 15 

 4.2. Termination. The covenants set forth in Subsection 4.1 shall terminate and be of
no further force or effect (i) immediately before the consummation of the IPO or (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon a
Deemed Liquidation Event, as such term is defined in the Company’s Certificate of Incorporation, whichever event occurs first. 
 5.
Additional Covenants. 
 5.1. Matters Requiring Investor Director Approval. As long as any Investor is entitled to designate an
Investor Director under the Voting Agreement, the Company hereby covenants and agrees with each of the Investors that it shall not, without approval of the Board, which approval must include the affirmative vote of a majority of Investor Directors
then in office: 
 (a) approve or make any material change to the budget of the Company; 

(b) adopt or amend any employee equity incentive plan or similar incentive arrangement, including increasing the number of shares reserved
for issuance thereunder, provided that the approval of a majority of the Investor Directors then in office shall not be required to increase the number of reserved shares up to a cumulative aggregate representing not more than 15% of the
Company’s fully diluted share capital. 
 (c) create any mortgage, pledge, lien or other security interest in any material asset of
the Company; 
 (d) guarantee, directly or indirectly, or permit any subsidiary to guarantee, directly or indirectly, any indebtedness
except for trade accounts of the Company or any subsidiary arising in the ordinary course of business; 
 (e) incur aggregate indebtedness
in excess of $100,000 that is not already included in a budget approved by the Board; 
 (f) otherwise enter into or be a party to any
transaction with any director, officer, or employee of the Company or any “associate” (as defined in Rule 12b-2 promulgated under the Exchange Act) of any such Person, except for transactions
contemplated by this Agreement, the Purchase Agreement, or employment or proprietary information agreements entered into with employees in the ordinary course of business; 

(g) hire, terminate, or change the terms of any existing employment or engagement of any executive officer, including without limitation
compensation of the executive officers, including approving any option grants or stock awards to executive officers; 
 (h) change the
principal business of the Company, enter new lines of business, or exit the current line of business; 
 (i) sell, assign, license, pledge,
or encumber material technology or intellectual property, other than licenses granted in the ordinary course of business; 
 (j) create any
committee of the Board; 
 (k) conduct an initial public offering of shares of the Company that is not a Qualified IPO; 

  
 16 

 (l) appoint or change the Company’s auditors or make any change to the accounting
principles adopted; 
 (m) change the signatory rights of the Company; or 

(n) adopt a business plan (including a plan in relation to the Company’s research, commercial, operational, strategic or clinical
goals). 
 The above provisions will also apply to any action by a subsidiary of the Company. 

5.2. Insurance. The Company shall maintain, from financially sound and reputable insurers Directors and Officers liability insurance in
the amount of $5,000,000, on terms and conditions satisfactory to the Investors holding a majority of the Preferred Stock, until such time as the Board and the Investors holding a majority of the Preferred Stock determine that such insurance should
be discontinued. 
 5.3. Employee Agreements. The Company will cause (i) each person now or hereafter employed by it or by any
subsidiary (or engaged by the Company or any subsidiary as a consultant/independent contractor) with access to confidential information and/or trade secrets to enter into a nondisclosure and proprietary rights assignment agreement; and (ii) to
the extent not detrimental to the Company in the jurisdiction of employment, each employee to enter into a one (1) year non-competition and non-solicitation
agreement, substantially in the form approved by the Board from time to time. The Company will take all reasonable steps to enforce such agreements (including such steps as may be required by a majority of Investor Directors then in office). Each
party hereto which is so employed or engaged by the Company agrees to enter into and comply with such agreements. 
 5.4. Employee
Stock. Unless otherwise approved by the Board, including a majority of Investor Directors then in office, all future employees and consultants of the Company who purchase, receive options to purchase, or receive awards of shares of the
Company’s capital stock after the date hereof shall be required to execute restricted stock or option agreements, as applicable, providing for (i) vesting of shares over a four (4) year period, with the first twenty-five percent (25%)
of such shares vesting following twelve (12) months of continued employment or service, and the remaining shares vesting in equal monthly installments over the following thirty-six (36) months, (ii)
a market stand-off provision substantially similar to that in Section 2.11; and (iii) a right of first refusal to the Company and certain of the Investors. 

5.5. Board Matters. Unless otherwise determined by the vote of a majority of the directors then in office including a majority of
Investor Directors then in office, the Board shall meet at least six (6) times per year and at least four (4) of the meetings shall take place in person. The Company shall reimburse the directors for all reasonable out-of-pocket travel expenses incurred (consistent with the Company’s travel policy) in connection with attending meetings of the Board. Each Investor Director shall be
entitled in such person’s discretion to be a member of any committee of the Board and any committee of the board of directors of any subsidiary of the Company. 

5.6. Successor Indemnification. If the Company or any of its successors or assignees consolidates with or merges into any other Person
and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall be made so that the successors and assignees of the Company assume the obligations of the Company with
respect to indemnification of members of the Board as in effect immediately before such transaction, whether such obligations are contained in the Company’s Bylaws, its Certificate of Incorporation, or elsewhere, as the case may be. 

  
 17 

 5.7. Right to Conduct Activities. The Company hereby agrees and acknowledges
that OrbiMed Israel Partners II, L.P. (“OrbiMed Israel”), OrbiMed Private Investments VI, LP (“Orbimed US”), Pontifax (Israel) IV L.P., Pontifax (Cayman) IV L.P., Pontifax
(China) IV L.P. (collectively, “Pontifax”), BioDiscovery 5 and Arix are professional investment funds, and as such invest in numerous portfolio companies, some of which may be deemed competitive with the
Company’s business (as currently conducted or as currently proposed to be conducted). The Company hereby agrees that, to the extent permitted under applicable law, OrbiMed Israel, Orbimed US, Pontifax, BioDiscovery 5 and Arix shall not be
liable to the Company for any claim arising out of, or based upon, (i) the investment by OrbiMed Israel, Orbimed US, Pontifax, BioDiscovery 5 or Arix in any entity competitive with the Company, or (ii) actions taken by any partner, officer
or other representative of OrbiMed Israel, Orbimed US, Pontifax, BioDiscovery 5 or Arix to assist any such competitive company, whether or not such action was taken as a member of the board of directors of such competitive company or otherwise, and
whether or not such action has a detrimental effect on the Company; provided, however, that the foregoing shall not relieve (x) any of the Investors from liability associated with the unauthorized disclosure of the Company’s confidential
information obtained pursuant to this Agreement, or (y) any director or officer of the Company from any liability associated with his or her fiduciary duties to the Company. 

5.8. FCPA. The Company represents that it shall not (and shall not permit any of its subsidiaries or affiliates or any of its or their
respective directors, officers, managers, employees, independent contractors, representatives or agents to) promise, authorize or make any payment to, or otherwise contribute any item of value to, directly or indirectly, to any third party,
including any Non-U.S. Official (as (as such term is defined in the U.S. Foreign Corrupt Practices Act of 1977, as amended (the “FCPA”)), in each case, in violation of the FCPA,
the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. The Company further represents that it shall (and shall cause each of its subsidiaries and affiliates to) cease all of its or their respective activities, as well as
remediate any actions taken by the Company, its subsidiaries or affiliates, or any of their respective directors, officers, managers, employees, independent contractors, representatives or agents in violation of the FCPA, the U.K. Bribery Act, or
any other applicable anti-bribery or anti-corruption law. The Company further represents that it shall (and shall cause each of its subsidiaries and affiliates to) maintain systems of internal controls (including, but not limited to, accounting
systems, purchasing systems and billing systems) to ensure compliance with the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. Upon request, the Company agrees to provide responsive information and/or
certifications concerning its compliance with applicable anti-corruption laws. The Company shall promptly notify each Investor if the Company becomes aware of any Enforcement Action (as defined in the Purchase Agreement). The Company shall, and
shall cause any direct or indirect subsidiary or entity controlled by it, whether now in existence or formed in the future, to comply with the FCPA. The Company shall use its best efforts to cause any direct or indirect subsidiary, whether now in
existence or formed in the future, to comply in all material respects with all applicable laws. 
 5.9. Termination of Covenants. The
covenants set forth in this Section 5 (except Subsection 5.6) shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO or (ii) when the Company first becomes subject to the periodic
reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon a Deemed Liquidation Event, as such term is defined in the Company’s Certificate of Incorporation, whichever event occurs first. 

6. Miscellaneous. 
 6.1.
Successors and Assigns. Unless otherwise specified herein, the rights under this Agreement may be assigned (but only with all related obligations) by a Holder to a transferee of Registrable Securities that (i) is an Affiliate of a
Holder; (ii) is a Holder’s Immediate Family Member or trust for the benefit of an individual Holder or one or more of such Holder’s Immediate Family Members; 

  
 18 

 
management company or a management company under common control with the management company of the Holder; provided, however, that (x) the Company is, within a reasonable time
after such transfer, furnished with written notice of the name and address of such transferee and the Registrable Securities with respect to which such rights are being transferred; and (y) such transferee agrees in a written instrument
delivered to the Company to be bound by and subject to the terms and conditions of this Agreement, including the provisions of Section 2.11. The terms and conditions of this Agreement inure to the benefit of and are binding upon the respective
successors and permitted assignees of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and permitted assignees any rights, remedies,
obligations or liabilities under or by reason of this Agreement, except as expressly provided herein. 
 6.2. Governing Law. This
Agreement shall be governed by the internal law of the State of Delaware. 
 6.3. Counterparts. This Agreement may be executed in two
(2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature
complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. 

6.4. Titles and Subtitles. The titles and subtitles used in this Agreement are for convenience only and are not to be considered in
construing or interpreting this Agreement. 
 6.5. Notices. All notices and other communications given or made pursuant to this
Agreement shall be in writing and shall be deemed effectively given upon the earlier of actual receipt or (i) personal delivery to the party to be notified; (ii) when sent, if sent by electronic mail during the recipient’s normal
business hours, and if not sent during normal business hours, then on the recipient’s next business day; (iii) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or
(iv) two (2) business day after the business day of deposit with an international courier service with written verification of receipt. All communications shall be sent to the respective parties at their addresses as set forth on Schedule A or
Schedule B (as applicable) hereto, with a copy which shall not constitute notice to the persons or entities specified in Schedule A or B, or to the principal office of the Company or by email to the attention of the Chief Executive Officer (email:
fchereau@logicbio.com), in the case of the Company, or to such email address or address as subsequently modified by written notice given in accordance with this Section 6.5. If notice is given to the Company, a copy (which shall not constitute
notice) shall be sent to Marc Rubenstein, Ropes & Gray LLP, Prudential Tower, 800 Boylston Street, Boston, MA 02199-3600 (email: marc.rubenstein@ropesgray.com). 

6.6. Amendments and Waivers. Unless expressly otherwise provided, any term of this Agreement may be amended and the observance of any
term of this Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company and the holders of at least sixty percent (60%) of the then outstanding
Preferred Stock (calculated on an as-converted basis); provided that the Company may in its sole discretion waive compliance with Section 2.12(c) (and the Company’s failure to object promptly
in writing after notification of a proposed assignment allegedly in violation of Section 2.12(c) shall be deemed to be a waiver); provided further that the Company may in its sole discretion amend Schedules A and B hereto from time to
time to add information regarding any additional party who became a party to this Agreement by executing and delivering a counterpart signature page in accordance with Subsection 6.9 or Subsection 6.9; and provided further that any provision
hereof may be waived by any waiving party on such party’s own behalf, without the consent of any other party. Notwithstanding the foregoing, the 

  
 19 

 
holders of at least sixty percent (60%) of the then outstanding shares of Series B Preferred Stock shall be required to waive the provisions of Section 3 and of Section 4 with respect
to some or all of the New Securities the Company proposes to offer or sell, and if the price specified in the Offer Notice is equivalent to a price lower than $1.499330 per share of Series B Preferred Stock, the consent of the holders of at least
ninety percent (90%) of the then outstanding shares of Series B Preferred Stock shall be required to waive the provisions of Section 4 (and this proviso may not be amended without the written consent of the holders of at least ninety percent
(90%) of the then outstanding shares of Series B Preferred Stock); provided further that the consent of the holders of a majority of the then outstanding shares of Series A Preferred Stock shall also be required to waive the provisions
of Section 4 with respect to such Shares of Series A Preferred Stock for Major Investors who hold Series A Preferred Stock (and this proviso may not be amended without the written consent of the holders of a majority of the then outstanding
shares of Series A Preferred Stock). Further notwithstanding the foregoing, this Agreement may not be amended or terminated and the observance of any term hereof may not be waived with respect to any Investor without the written consent of such
Investor, unless such amendment, termination, or waiver applies to all Investors in the same fashion (it being agreed that a waiver of the provisions of Section 4 with respect to a particular transaction shall be deemed to apply to all
Investors in the same fashion if such waiver does so by its terms, notwithstanding the fact that certain Investors may nonetheless, by agreement with the Company, purchase securities in such transaction). The Company shall give prompt notice of any
amendment or termination hereof or waiver hereunder to any party hereto that did not consent in writing to such amendment, termination, or waiver. Any amendment, termination, or waiver effected in accordance with this Section 6.6 shall be
binding on all parties hereto, regardless of whether any such party has consented thereto. No waivers of or exceptions to any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed to be or construed as a
further or continuing waiver of any such term, condition, or provision. 
 6.7. Severability. In case any one or more of the
provisions contained in this Agreement is for any reason held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid, illegal,
or unenforceable provision shall be reformed and construed so that it will be valid, legal, and enforceable to the maximum extent permitted by law. 

6.8. Aggregation of Stock. All shares of Registrable Securities held or acquired by Affiliates shall be aggregated together for the
purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as among themselves in any manner they deem appropriate. 

6.9. Additional Parties. Notwithstanding anything to the contrary contained herein, if the Company issues additional shares of Common
Stock or Preferred Stock after the date hereof, as a condition to the issuance of such shares the Company shall require that any purchaser of such shares to become a party to this Agreement by executing and delivering a counterpart signature page
hereto, thereby agreeing to be bound by and subject to the terms of this Agreement as a Common Holder (in the event of an issue of shares of Common Stock) or Investor (in the event of an issue of shares of Preferred Stock) and a Stockholder
hereunder. In either event, each such person shall thereafter be deemed a Common Holder or Investor (as applicable) and a Stockholder for all purposes under this Agreement. 

6.10. Transfers. Each transferee or assignee of any shares held by a party to this Agreement shall be subject to the terms hereof, and,
as a condition precedent to the Company’s recognizing such transfer, each transferee or assignee shall agree in writing to be subject to each of the terms of this Agreement by executing and delivering a counterpart signature page hereto,
thereby agreeing to be bound by and subject to the terms of this Agreement. Upon the execution and delivery of a counterpart signature by any transferee, such transferee shall be deemed to be a party hereto and shall be 

  
 20 

 
deemed to be an Investor and Stockholder (in the event of a transfer of shares of Preferred Stock), or Common Holder and Stockholder (in the event of a transfer if shares of Common Stock). The
Company shall not permit the transfer of shares on its books or issue a new certificate representing any such shares unless and until such transferee shall have complied with the terms of this Section 6.10. 

6.11. Entire Agreement. This Agreement (including any Schedules and Exhibits hereto) constitutes the full and entire understanding and
agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is expressly canceled. 

6.12. Dispute Resolution. The parties (a) hereby irrevocably and unconditionally submit to the jurisdiction of the state courts of
State of Delaware for the purpose of any suit, action or other proceeding arising out of or based upon this Agreement, (b) agree not to commence any suit, action or other proceeding arising out of or based upon this Agreement except in the
state courts of State of Delaware and (c) hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the
above-named courts, that its property is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or
the subject matter hereof may not be enforced in or by such court. 
 WAIVER OF JURY TRIAL: EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF
ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT, THE OTHER TRANSACTION AGREEMENTS, THE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE
ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS (INCLUDING
NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION HAS BEEN FULLY DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER
WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. 

Each party will bear its own costs in respect of any disputes arising under this Agreement. The prevailing party shall be entitled to
reasonable attorney’s fees, costs, and necessary disbursements in addition to any other relief to which such party may be entitled. 

6.13. Delays or Omissions. No delay or omission to exercise any right, power, or remedy accruing to any party under this Agreement,
upon any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such non-breaching or non-defaulting party, nor
shall it be construed to be a waiver of or acquiescence to any such breach or default, or to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default
theretofore or thereafter occurring. All remedies, whether under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative. 

  
 21 

 6.14. Acknowledgment. The Company acknowledges that certain Investors are in the
business of venture capital investing and therefore review the business plans and related proprietary information of many enterprises, including enterprises which may have products or services which compete directly or indirectly with those of the
Company. Nothing in this Agreement shall preclude or in any way restrict the Investors from investing or participating in any particular enterprise whether or not such enterprise has products or services which compete with those of the Company 

6.15. Pay-to-Play. The parties hereto
acknowledge and agree that the terms of this Agreement are subject to the provisions of Article IV(B), Section 6 of the Certificate of Incorporation. 

6.16. Termination of Previous Agreement. The undersigned, being the Company, all the Investors (as defined in the Previous Agreement)
and all the Common Holders (as defined in the Previous Agreement) agree that the Previous Agreement is hereby terminated as of the date first written above (the “Termination Date”). From and after the Termination Date,
the Previous Agreement will be of no further force or effect, and all rights and obligations of each of the parties thereunder shall terminate, except for any rights and obligations of the parties that are expressly designated thereunder to survive
the termination of the Previous Agreement. 
 [Remainder of Page Intentionally Left Blank] 

  
 22 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
 COMPANY: 
  

			
	LOGICBIO THERAPEUTICS INC.
		
	By:	 	/s/ Frederic Chereau
		
	Name:	 	Frederic Chereau
		
	Title:	 	Chief Executive Officer

 SIGNATURE PAGE TO INVESTORS’
RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	COMMON HOLDERS:
		
	Signature:	 	/s/ Mark A. Kay
	Name:	 	Mark Kay
		
	Signature:	 	 
	Name:	 	Adi Barzel
		
	Signature:	 	 
	Name:	 	Leszek Lisowski
		
	Signature:	 	 
	Name:	 	Frederic Chereau
		
	Signature:	 	 
	Name:	 	Leon Chen
		
	Signature:	 	 
	Name:	 	Josh Checketts
		
	Signature:	 	 
	Name:	 	Matt Porteus
	
		
	Signature:	 	 
	Name:	 	Richard Voit

 SIGNATURE PAGE TO INVESTORS’
RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	COMMON HOLDERS:
		
	Signature:	 	 
	Name:	 	Mark Kay
		
	Signature:	 	/s/ Adi Barzel
	Name:	 	Adi Barzel
		
	Signature:	 	 
	Name:	 	Leszek Lisowski
		
	Signature:	 	 
	Name:	 	Frederic Chereau
		
	Signature:	 	 
	Name:	 	Leon Chen
		
	Signature:	 	 
	Name:	 	Josh Checketts
		
	Signature:	 	 
	Name:	 	Matt Porteus
	
		
	Signature:	 	 
	Name:	 	Richard Voit

 SIGNATURE PAGE TO INVESTORS’
RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	COMMON HOLDERS:
		
	Signature:	 	 
	Name:	 	Mark Kay
		
	Signature:	 	 
	Name:	 	Adi Barzel
		
	Signature:	 	/s/ Leszek Lisowski
	Name:	 	Leszek Lisowski
		
	Signature:	 	 
	Name:	 	Frederic Chereau
		
	Signature:	 	 
	Name:	 	Leon Chen
		
	Signature:	 	 
	Name:	 	Josh Checketts
		
	Signature:	 	 
	Name:	 	Matt Porteus
	
		
	Signature:	 	 
	Name:	 	Richard Voit

 SIGNATURE PAGE TO INVESTORS’
RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	COMMON HOLDERS:
		
	Signature:	 	 
	Name:	 	Mark Kay
		
	Signature:	 	 
	Name:	 	Adi Barzel
		
	Signature:	 	 
	Name:	 	Leszek Lisowski
		
	Signature:	 	/s/ Frederic Chereau
	Name:	 	Frederic Chereau
		
	Signature:	 	 
	Name:	 	Leon Chen
		
	Signature:	 	 
	Name:	 	Josh Checketts
		
	Signature:	 	 
	Name:	 	Matt Porteus
	
		
	Signature:	 	 
	Name:	 	Richard Voit

 SIGNATURE PAGE TO INVESTORS’
RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	COMMON HOLDERS:
		
	Signature:	 	 
	Name:	 	Mark Kay
		
	Signature:	 	 
	Name:	 	Adi Barzel
		
	Signature:	 	 
	Name:	 	Leszek Lisowski
		
	Signature:	 	 
	Name:	 	Frederic Chereau
		
	Signature:	 	/s/ Leon Chen
	Name:	 	Leon Chen
		
	Signature:	 	 
	Name:	 	Josh Checketts
		
	Signature:	 	 
	Name:	 	Matt Porteus
	
		
	Signature:	 	 
	Name:	 	Richard Voit

 SIGNATURE PAGE TO INVESTORS’
RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	COMMON HOLDERS:
		
	Signature:	 	 
	Name:	 	Mark Kay
		
	Signature:	 	 
	Name:	 	Adi Barzel
		
	Signature:	 	 
	Name:	 	Leszek Lisowski
		
	Signature:	 	 
	Name:	 	Frederic Chereau
		
	Signature:	 	 
	Name:	 	Leon Chen
		
	Signature:	 	/s/ Josh Checketts
	Name:	 	Josh Checketts
		
	Signature:	 	 
	Name:	 	Matt Porteus
	
		
	Signature:	 	 
	Name:	 	Richard Voit

 SIGNATURE PAGE TO INVESTORS’
RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	COMMON HOLDERS:
		
	Signature:	 	 
	Name:	 	Mark Kay
		
	Signature:	 	 
	Name:	 	Adi Barzel
		
	Signature:	 	 
	Name:	 	Leszek Lisowski
		
	Signature:	 	 
	Name:	 	Frederic Chereau
		
	Signature:	 	 
	Name:	 	Leon Chen
		
	Signature:	 	 
	Name:	 	Josh Checketts
		
	Signature:	 	 /s/ Matthew Porteus

	Name:	 	Matt Porteus
	
		
	Signature:	 	 
	Name:	 	Richard Voit

 SIGNATURE PAGE TO INVESTORS’
RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	COMMON HOLDERS:
		
	Signature:	 	 
	Name:	 	Mark Kay
		
	Signature:	 	 
	Name:	 	Adi Barzel
		
	Signature:	 	 
	Name:	 	Leszek Lisowski
		
	Signature:	 	 
	Name:	 	Frederic Chereau
		
	Signature:	 	 
	Name:	 	Leon Chen
		
	Signature:	 	 
	Name:	 	Josh Checketts
		
	Signature:	 	 
	Name:	 	Matt Porteus
	
		
	Signature:	 	 /s/ Richard Voit

	Name:	 	Richard Voit

 SIGNATURE PAGE TO INVESTORS’
RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
 INVESTORS: 
  

			
	ORBIMED ISRAEL PARTNERS II, L.P.
		
	By:	 	OrbiMed Israel GP II, L.P., its General Partner
		
	By:	 	OrbiMed Advisors Israel II Limited, its General Partner
		
	By:	 	 /s/ Nissim Darvish

	Name:	 	Nissim Darvish
	Title:	 	Senior Managing Director
		
	By:	 	 /s/ Erez Chimovits

	Name:	 	Erez Chimovits
	Title:	 	Senior Managing Director

 SIGNATURE PAGE TO INVESTORS’
RIGHTS AGREEMENT 

 INVESTORS: 
  

					
	ORBIMED PRIVATE INVESTMENTS VI, LP
		
	By:	 	OrbiMed Capital GP VI LLC, its General Partner
			
		 	By:	 	OrbiMed Advisors LLC, its Managing Member
		
	By:	 	/s/ Carl Gordan
	Name:	 	Carl Gordan
	Title:	 	Member

 SIGNATURE PAGE TO INVESTORS’
RIGHTS AGREEMENT 

 INVESTORS: 
  

			
	ARIX BIOSCIENCE, INC
		
	By:	 	/s/ J Rawlingson
	Name:	 	J Rawlingson
	Title:	 	Director

 SIGNATURE PAGE TO INVESTORS’
RIGHTS AGREEMENT 

 INVESTORS: 
  

			
	 THE BOARD OF TRUSTEES OF THE

LELAND STANFORD JUNIOR UNIVERSITY (PVF)

		
	By:	 	/s/ Sabrina Liang
	Name:	 	Sabrina Liang
	Title:	 	Director, School and Department Funds, Stanford Management Company

 SIGNATURE PAGE TO INVESTORS’
RIGHTS AGREEMENT 

 INVESTORS: 
  

			
	PONTIFAX (ISRAEL) IV L.P.
		
	By:	 	/s/ Tomer Kariv
	Name:	 	Tomer Kariv
	Title:	 	Managing Partner
	
	PONTIFAX (CAYMAN) IV L.P.
		
	By:	 	/s/ Tomer Kariv
	Name:	 	Tomer Kariv
	Title:	 	Managing Partner
	
	PONTIFAX (CHINA) IV L.P.
		
	By:	 	/s/ Tomer Kariv
	Name:	 	Tomer Kariv
	Title:	 	Managing Partner

 SIGNATURE PAGE TO INVESTORS’
RIGHTS AGREEMENT 

 INVESTORS: 
  

			
	SBI JI Innovation Fund Limited Partnership
		
	By:	 	 /s/ Masafuyu Tanaka

	Name:	 	Masafuyu Tanaka
	Title:	 	Director of SBI JI Innovation Partners Ltd.

 SIGNATURE PAGE TO INVESTORS’
RIGHTS AGREEMENT 

 INVESTORS: 
  

			
	BIODISCOVERY 5
	
	By: Edmond de Rothschild Investment Partners,
	Its Management Company
		
	By:	 	/s/ Raphaël Wisniewski
	Name:	 	Raphaël Wisniewski
	Title:	 	Partner

 SIGNATURE PAGE TO INVESTORS’
RIGHTS AGREEMENT 

 SCHEDULE A 

Investors 
  

					
	 Name
	  	 Address
	  	 Email

	OrbiMed Israel Partner II, LP	  	OrbiMed Israel Partners II, LP	  	DarvishN@OrbiMed.com
		  	c/o OrbiMed Israel Partners	  	
		  	Limited	  	
		  	Attention : Nissim Darvish	  	
		  	89 Medinat HaYehudim st.	  	
		  	Building E, 11th Floor	  	
		  	Herzliya 46766	  	
			
	The Board of Trustees of the	  	Stanford Management Company	  	direct@smc.stanford.edu
	Leland Stanford Junior	  	Attn: Sabrina Liang	  	
	University (PVF)	  	635 Knight Way	  	
		  	Stanford, CA 94305-7297	  	
			
	Arix Bioscience, Inc.	  	250 West 55th Street, 33rd Floor,	  	Daniel@arixbioscience.com
		  	New York, NY 10019	  	
			
	OrbiMed Private Investments VI,	  	OrbiMed Advisors LLC	  	SoA@OrbiMed.com
	LP	  	601 Lexington Avenue,	  	
		  	54th Floor	  	
		  	New York, NY 10022	  	
			
	Pontifax (Israel) IV L.P.	  	14 Shenkar St.	  	tomer@pontifax.com
		  	Herzelia, Israel	  	
		  	Attention: Tomer Kariv	  	
			
	Pontifax (Cayman) IV L.P.	  	14 Shenkar St.	  	tomer@pontifax.com
		  	Herzelia, Israel	  	
		  	Attention: Tomer Kariv	  	
			
	Pontifax (China) IV L.P.	  	14 Shenkar St.	  	tomer@pontifax.com
		  	Herzelia, Israel	  	
		  	Attention: Tomer Kariv	  	
			
	BioDiscovery 5	  	Edmond de Rothschild	  	s.ioannidou@edr.com
		  	Investment Partners	  	
		  	Attention: Sofia Ioannidou	  	
		  	47 rue du Faubourg Saint-	  	
		  	Honoré 75008 Paris, France	  	
			
	SBI JI Innovation Fund Limited	  	11 Ha’manofim St. Akerstein	  	Masa@sbi-ji.co.il
	Partnership	  	Tower B. 3rd Floor, Herzelya,	  	
		  	Israel	  	

 SCHEDULE B 

Common Holders 
  

							
	 Name
	  	 Address
	  	 Phone Number
	  	 Email

	 Mark Kay
	  	 1071 Peninsular CT
	  	650-823-1993	  	 markay@stanford.edu

				
		  	 Los Altos, CA 94024
	  		  	
				
	 Adi Barzel
	  	 Beit Oren Street 8/1
	  	972-50-6847555	  	 adibarzel@gmail.com

				
		  	 Hod Hasharon, Israel,
	  		  	
		  	 4538421
	  		  	
				
	 Leszek Lisowski
	  	 2/127 Foveaux Street
	  	+61-0-428-338-594	  	 llisowski@logicbiotherapeutics.com

		  	 Surry Hills, NSW
	  		  	
		  	 2010, Australia
	  		  	
				
	 Frederic Chereau
	  	 7225 Encelia DR La
	  	617-230-6546	  	 fchereau@logicbio.com

		  	 Jolla, CA 92037
	  		  	
				
	 Leon Chen
	  	 209 Lexington Drive,
	  		  	 chenL@orbimed.com

		  	 Menlo Park, CA
	  		  	
		  	 94025
	  		  	
				
	 Josh Checketts
	  	 13358 S Stone Hayes
	  		  	 joshchecketts@gmail.com

		  	 Ct Herriman, UT
	  		  	
		  	 84096
	  		  	
				
	 Matt Porteus
	  	 121 Peter Coutts Cir
	  		  	 mporteus@stanford.edu

		  	 Stanford, CA 94305
	  		  	
				
	 Richard Voit
	  	 39 Quirk St
	  		  	 Richard.voit@gmail.com

		  	 Watertown, MA 02472

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00287-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00287-of-00352.parquet"}]]